ArticleslgStudy

chemistry

Renzapride

Renzapride is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Renzapride rather than just read about it. In short: Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.

Renzapride — main illustration
Renzapride — illustration

Key takeaways

  • Renzapride belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Renzapride to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Renzapride from memory before moving on to harder problems.

Reference excerpt

Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors. Renzapride was being developed by Alizyme plc of the United Kingdom. In May 2016, EndoLogic LLC, a US-based pharmaceutical and medical device company, acquired the US and worldwide patent rights to Renzapride. Endologic confirmed the cardiac safety of renzapride through a “Thorough QTc” study and sold the rights to Atlantic Healthcare plc in 2019, a specialist pharmaceutical company. Ambrose Healthcare acquired renzapride in 2024. It is focusing on the development of renzapride for the management of gastrointestinal (GI) motility in patients with cystic fibrosis, for which there is no approved therapy.

Clinical trials In nine diabetic patients with autonomic neuropathy, renzapride reduced the mean lag phase of gastric emptying by 20–26 min at all doses (P < 0.01) In Phase 2a studies on subjects with constipation Renzapride was shown to accelerate colonic transit (p=0.016 vs placebo P=0.009) (Ref: ATL 1251/001/CL) as well as increase daily stool frequency (p<0.005) (Ref: ATL 1251/025/CL) Renzapride has been assessed in Phase II clinical trials with a total of 578 patients with constipation-predominant irritable bowel syndrome (IBS-C). As compared with placebo, the treatment groups reported better relief of their overall symptoms, namely abdominal pain and discomfort, increase in the number of pain free days, improved stool frequency, consistency and ease of passage of bowel movements. There were no significant differences in the reported Serious Adverse Events between treatment and placebo groups. In the largest of these Phase II trials, 510 subjects with IBS-C received either 1, 2 or 4 mg QD renzapride, or placebo QD for 12 weeks. The Weekly responder rate based on subject's assessment of whether they had relief from abdominal pain and/or discomfort associated with IBS during weeks 5-12 was 56% (renzapride 4 mg) vs 49% (placebo). For females the treatment effect was larger, 61% (renzapride 4 mg) vs 49% (placebo). Statistically significant effects in favour of renzapride were observed for improvements in stool consistency and increased bowel movements. In the Phase III clinical trial in IBS-C, 1798 female patients received either 2 or 4 mg Renzapride, or placebo once daily, for 12 weeks. The mean number of months with relief of overall symptoms was 0.6, 0.55 and 0.44 for renzapride 2 mg twice a day, renzapride 4 mg once a day and placebo, respectively, with both renzapride doses being statistically superior to placebo (p=0.004 and p=0.027, respectively). On responder analysis, the proportion of responders was 33.2%, 29.8%, and 24.3% for renzapride 2 mg twice a day, renzapride 4 mg once a day and placebo, respectively. The 8.9% delta between renzapride 2 mg twice daily and placebo compares favourably with other FDA approved therapies (Ford ).

See also List of investigational Parkinson's disease drugs

References

Illustrations

Renzapride illustration

Worked examples

Example 1 — a first encounter with Renzapride

Start with the simplest possible case. Write down what Renzapride claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Renzapride before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Renzapride ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Renzapride

In research
Renzapride appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Renzapride in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Renzapride is common in secondary-school and first-year university syllabi. It links to neighbouring topics 5-HT3 antagonists, Abandoned drugs, Anilines, so understanding it makes those chapters shorter.
In everyday life
Look for Renzapride outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Renzapride in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Renzapride means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Renzapride out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Renzapride in simple terms?

Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.

Why does Renzapride matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Renzapride?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Renzapride.

Tags

  • 5-HT3 antagonists
  • Abandoned drugs
  • Anilines
  • Benzamides
  • Chloroarenes
  • Drugs not assigned an ATC code
  • Heterocyclic compounds with 2 rings
  • Nitrogen heterocycles
  • Phenol ethers

Keep exploring